Chronic Spontaneous Urticaria Market Summary
The Chronic Spontaneous Urticaria market has emerged as one of the most dynamically evolving segments within immunodermatology. The Chronic Spontaneous Urticaria market size in the 7 Major Markets (7MM) – comprising the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan – was valued at approximately USD 2,000 million in 2025, and is projected to grow significantly over the forecast period from 2026 to 2036, propelled by robust pipeline activity, expanding diagnosis rates, and the introduction of breakthrough targeted therapies.
The US market alone accounted for approximately USD 1 billion in 2025, representing the largest single-country share within the 7MM. The US CSU market is expected to grow at a CAGR of 15% during the forecast period, driven by increasing awareness of the disease, favorable regulatory frameworks, and the commercial launch of emerging therapies, including newly approved biologics. Meanwhile, the total market size of CSU in EU4 and the UK was calculated at approximately USD 600 million in 2025, representing nearly 30% of the total 7MM market revenue – reflecting a steadily maturing treatment landscape in these regions.
Chronic Spontaneous Urticaria Understanding and Treatment Algorithm
Urticaria is a common and heterogeneous inflammatory skin disorder that presents with wheals, angioedema, or both, resulting from the activation and degranulation of skin mast cells and the subsequent release of histamine and other inflammatory mediators. It is classified as acute or chronic, depending on whether symptom episodes last less than or more than six weeks, respectively.
Chronic urticaria is either spontaneous or inducible, persists beyond six weeks, and typically continues for more than a year. The condition significantly impacts quality of life and is associated with psychiatric comorbidities, high healthcare utilization, and considerable socio-economic burden. Women are twice as likely as men to receive a CSU diagnosis, with most patients first developing symptoms between the ages of 20 and 40.
The etiology of Chronic Spontaneous Urticaria remains incompletely understood, though autoimmune mechanisms play a central role. Both IgG-specific and IgE-specific autoantibodies against a diverse array of antigens – including those found on mast cells and basophils – are implicated in the condition’s pathogenesis. Other potential triggers include medications, infections, stress, and temperature changes.
Diagnosis is based on physical examination and medical history, supplemented by blood tests, allergy testing, skin biopsies, and thyroid function assessments. Autologous serum skin tests (ASST) and in vitro basophil histamine release assays (BHRA) are also recommended tools. Validated instruments such as the Urticaria Activity Score (UAS) and the Urticaria Control Test (UCT) assist in measuring disease severity, control, and quality-of-life impact.
Treatment follows a stepwise protocol. First-line therapy consists of second-generation H1-antihistamines, with up-dosing to fourfold recommended for non-responders. Omalizumab, an anti-IgE monoclonal antibody, serves as the preferred second-line agent for antihistamine-refractory CSU, offering effective, well-tolerated, and long-term symptom control. Cyclosporine is reserved for severe, treatment-resistant cases, while short courses of systemic corticosteroids may manage acute flares. Leukotriene receptor antagonists such as montelukast provide modest adjunctive benefit.
Chronic Spontaneous Urticaria Epidemiology
The Chronic Spontaneous Urticaria market research model is patient-based, making epidemiological precision a cornerstone of market sizing. According to DelveInsight’s estimates, the total diagnosed prevalent cases of chronic urticaria across the 7MM reached approximately 4.8 million in 2025, with numbers anticipated to rise through 2036.
Key epidemiological findings include:
- The US accounted for approximately 19% of total diagnosed prevalent chronic urticaria cases, with around 920,000 cases in 2025
- EU4 and the UK collectively represented approximately 39% of total chronic urticaria cases in the 7MM in 2025
- Japan accounted for nearly 42% of total chronic urticaria cases, and approximately 37% of total diagnosed prevalent CSU cases across the 7MM in 2025
- The US recorded approximately 610,000 diagnosed prevalent CSU cases in 2025, with growth projected through 2036
- In EU4 and the UK, the age group ≥60 years represented the largest number of diagnosed CSU cases in 2025, with nearly 450,000 cases, followed by the 50–59 years age group with around 250,000 cases
- Among EU4 and the UK countries, Germany reported the highest number of diagnosed prevalent CSU cases at approximately 390,000, while Spain reported the lowest at approximately 190,000 in 2025
These demographic and geographic distribution patterns reflect both the aging of susceptible populations and growing diagnostic awareness – factors that will continue to shape Chronic Spontaneous Urticaria market insight analyses through the forecast period.
Chronic Spontaneous Urticaria Market Recent Developments and Breakthroughs
The CSU treatment space has witnessed remarkable momentum, with multiple pivotal regulatory and clinical milestones recorded in recent months:
- January 2026: Jasper Therapeutics reported updated results from the Phase Ib/IIa BEACON study and its open-label extension, demonstrating that briquilimab delivered sustained disease control in CSU, with additional patients achieving complete responses and marked reductions in UAS7 scores at 12 weeks
- November 2025: The European Commission approved DUPIXENT (dupilumab) for the treatment of moderate-to-severe CSU in adults and adolescents aged 12 years and above with inadequate response to H1 antihistamines and naive to anti-IgE therapy, positioning DUPIXENT as a first-line targeted treatment option in the EU
- April 2025: The US FDA approved Dupixent® (dupilumab) by Regeneron Pharmaceuticals and Sanofi for treating CSU in adults and adolescents aged 12 and older who remain symptomatic despite H1 antihistamine treatment, marking the first new targeted therapy for CSU approved in the US in over a decade
Marketed Chronic Spontaneous Urticaria Drugs
- DUPIXENT (dupilumab) – Sanofi/Regeneron Pharmaceuticals
DUPIXENT is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4Rα subunit shared by both the IL-4 and IL-13 receptor complexes, thereby suppressing the Type I and Type II signaling pathways underlying allergic and type 2 inflammatory responses.
First approved for CSU in February 2024 in Japan – making Japan the first country globally to authorize its use for this indication – DUPIXENT subsequently received US FDA approval in April 2025, becoming the first new targeted therapy for CSU in more than a decade. The approvals were supported by Phase III trial data demonstrating significant and clinically meaningful reductions in itch scores compared to placebo. DUPIXENT is also approved across multiple other indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.
Emerging Chronic Spontaneous Urticaria Drugs
The CSU pipeline is among the most active in immunodermatology, with several differentiated mechanisms in late-stage development that are shaping evolving Chronic Spontaneous Urticaria market trends.
- Barzolvolimab (CDX-0159) – Celldex Therapeutics Barzolvolimab is a humanized monoclonal antibody targeting KIT, a receptor tyrosine kinase essential for mast cell survival, activation, and tissue recruitment. By selectively inhibiting KIT, barzolvolimab directly depletes mast cells – the central drivers of CSU pathophysiology. In November 2025, Celldex presented Phase II data at ACAAI demonstrating rapid, profound, and durable urticaria control in antihistamine-refractory CSU, with sustained efficacy observed beyond treatment discontinuation. Significant improvements in UCT7 scores were reported, with high rates of complete and well-controlled disease maintained through week 52 and persisting to week 76, supporting barzolvolimab’s potential as a disease-modifying therapy.
- Rilzabrutinib – Sanofi Rilzabrutinib is an oral, reversible covalent BTK inhibitor with first- or best-in-class potential across multiple immune-mediated diseases. Developed using Sanofi’s TAILORED COVALENCY technology, it selectively targets BTK expressed in B cells and mast cells while minimizing off-target effects. In February 2024, Sanofi presented positive Phase II RILECSU study data at the AAAAI Annual Meeting, demonstrating that rilzabrutinib significantly improved itch, hives, and overall urticaria symptoms in adults with moderate-to-severe CSU who remained symptomatic despite H1 antihistamine treatment, paving the way for Phase III evaluation.
- Briquilimab – Jasper Therapeutics Briquilimab is a Phase Ib/IIa investigational monoclonal antibody targeting the SCF/CD117 (c-Kit) pathway, designed to reduce mast cell survival in the skin – a key driver in antihistamine-refractory CSU. Updated BEACON study data reported in January 2026 confirmed sustained disease control, with complete responses and marked UAS7 reductions at 12 weeks.
Leading Chronic Spontaneous Urticaria Companies
The competitive landscape of the CSU market features a robust mix of established pharmaceutical leaders and specialized biotechnology firms. The leading Chronic Spontaneous Urticaria companies developing therapies include Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company, and others. These organizations are collectively advancing a diverse array of therapeutic approaches – from anti-IgE and anti-IL-4/13 biologics to BTK inhibitors and KIT-targeting antibodies – significantly enriching the pipeline that will define the next decade of CSU care.
Conclusion
The global Chronic Spontaneous Urticaria market is at a pivotal inflection point. Backed by a robust pipeline, transformative regulatory approvals, and growing epidemiological recognition, the market is well-positioned for sustained and significant growth through 2036. The approval of dupilumab in both the US and EU marks the most consequential shift in CSU treatment in over a decade, while next-generation agents such as barzolvolimab and rilzabrutinib signal a deeper mechanistic understanding of the disease. As patient identification improves and treatment paradigms evolve from symptom management to potential disease modification, stakeholders – from payers to pharma developers – must remain attuned to rapidly shifting Chronic Spontaneous Urticaria market trends to capture value in this expanding space.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
